Syndivia is dedicated to enhancing treatment options for patients with solid tumors. They specialize in utilizing their proprietary and unique GeminiMab™ technology — the first and only hinge-region Cys229 site-specific ADC technology applicable to native monoclonal antibodies. Specifically, they take advantage of the distinctive GeminiMab™-DAR1 ADCs, which offer improved antitumor efficacy and reduced toxicity.

The key technology behind Syndivia’s unique site-specific approach is GeminiMab™, the first and only technology for hinge-region site-specific conjugation (2xCys229), enabling unprecedented efficiency and scope in creating site-specific DAR1 ADCs.

Their proprietary candidates include:

1. SDV2102: GeminiMab anti-PSMA ADC (mCRPC, GBM, HCC)

2. SDV2103: GeminiMab anti-Trop2 ADC (NSCLC)

–  Therapeutic areas: Antibody-drug-conjgutes, Oncology

–  Based in: Strasbourg (FRANCE)

–  Employees: 1 – 10

–  Created in: 2014